Остеопороз и остеопатии (Dec 2014)

THE INFLUENCE OF AWARENESS OF PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS ABOUT THE MAGNITUDE OF THE FRAX 10-YEAR ABSOLUTE RISK OF FRACTURE ON THE DECISION TO START AND THE ADHERENCE TO ANTIOSTEOPOROTIC TREATMENT (INTERIM RESULTS OF «CRYSTAL» STUDY)

  • O M Lesnyak,
  • E N Khoseva,
  • L V Menshikova,
  • T V Antonova,
  • I M Ivygina,
  • E V Kapustina,
  • I I Veytsman,
  • I B Belousova,
  • E I Sitnikova,
  • S Yu Shkireeva,
  • O B Bozhko,
  • N V Bezlyudnaya,
  • L Kh Gilyazeva,
  • N Yu Kozhevnikova,
  • Yu V Titova,
  • E N Chikina,
  • N N Kalinina,
  • I E Prokhorova

DOI
https://doi.org/10.14341/osteo201427-10
Journal volume & issue
Vol. 17, no. 2
pp. 7 – 10

Abstract

Read online

To assess the influence of informing patients with postmenopausal osteoporosis about the their probability of 10-year absolute fracture risk calculated by FRAX tool on the patient ’s decision to start treatment and their adherence to therapy during 3 years of follow-up. Materials and Methods. Multicenter open randomized trial included 417 women (mean age 65.9 years). Patients of the 1 group (n=191) were informed about the value of their absolute risk of fracture by FRAX. Patients of the 2 group (the control; n=196) got usual advice and recommendations without calculating FRAX. All patients were recommended to take alendronate in a standard dose (70 mg a week) and calcium/vitamin D supplements. Results. During the first three months after initial visit 96.4% of patients started their treatment. The adherence to treatment at sixth month was 7% higher in the group 1; the compliance in the group 1 was 8% higher, than in the control group. 6.4% of patients developed adverse drug reactions, which led to cancellation of therapy in only 2.9% of patients.

Keywords